Free Trial
NASDAQ:CGTX

Cognition Therapeutics Q3 2023 Earnings Report

Cognition Therapeutics logo
$0.32 +0.00 (+1.02%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$0.32 +0.00 (+0.25%)
As of 06:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cognition Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Cognition Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cognition Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 2, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Cognition Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cognition Therapeutics Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
B. Riley Issues Negative Forecast for CGTX Earnings
See More Cognition Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email.

About Cognition Therapeutics

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

View Cognition Therapeutics Profile

More Earnings Resources from MarketBeat